Publications

5543 Results

Comparing the Prognostic and Predictive Utility of Serum Thymidine Kinase 1 and CA 15-3 in Patients with Hormone Receptor Positive Metastatic Breast Cancer Starting First-Line Endocrine Therapy in SWOG S0226

Authors
E Cobain;W Barlow;C Paoletti;M Bergqvist;A Williams;H Ritzen;R Mehta;J Gralow;G Hortobagyi;K Albain;L Pusztai;P Sharma;A Godwin;A Thompson;D Hayes;J Rae
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 1076); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Breast
Study Number(s)
S0226

Prostate-Specific Antigen at 3 & 7 months (PSA-3mo, PSA-7mo) Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treated with Androgen Deprivation With or Without Orteronel (SWOG S1216)

Authors
M Parikh;C Tangen;M Hussain;S Gupta;Y Jo;A Harzstark;C Paller;S George;M Zibelman;H Cheng;B Maughan;J Zhang;R Pachynski;A Bryce;D Lin;D Quinn;I Thompson;T Dorff;P Lara;N Agarwal
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 5074); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1216

Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide

Authors
A Goldkorn;C Tangen;M Plets;D Bsteh;T Xu;J Pinski;S Ingles;T Triche;G MacVicar;D Vaena;A Crispino;D McConkey;P Lara;M Hussain;D Quinn;T Dorff;I Thompson;N Agarwal
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 5080); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1216

Pathologic Concordance Rate and Outcomes by Histologic Subtype in Advanced Papillary Renal Cell (pRCC) Carcinoma: an Analysis from the SWOG S1500 (PAPMET) Trial

Authors
A Tripathi;C Tangen;X Li;M Tretiokova;P Humphrey;A Adeniran;P Barata;S Gulati;C Bergerot;D Pruthi;I Thompson;P Lara;S Pal;B Shuch
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 4562); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1500

Chemotherapy Dose Density is Prognostic for Patients with Resectable Pancreas Cancer: A Secondary Analysis of SWOG S1505

Authors
SH Patel;S Colby;D Sohal;K Guthrie;L Kachnic;E Chiorean;A Lowy;F Rocha;P Philip;S Ahmad
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 4158); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
S1505

Change in RECIST Tumor Size Correlates Linearly with Survival in Patients Treated with Checkpoint Inhibitor Therapy (SWOG S1609)

Authors
M Othus;S Patel;Y Chae;E Dietrich;H Streicher;E Sharon;R Kurzrock
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 2504); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
Year
2023
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Desmoid Tumors (Cohort 27)

Authors
YK Chae;M Othus;S Patel;B Powers;C-T Hsueh;R Govindarajan;S Bucur;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 11516); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Vulvar Cancers

Authors
Y Chae;M Othus;S Patel;R Edwards;J Scalici;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 5517); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

HERCULES: A prostate cancer (PC) sequencing panel for parallel analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) (SWOG S1802)

Authors
Bsteh;J Buckley;D Ostrow;J Parmentier;S Maganti;S Mitchell;S Sadis;J Smith;J Ni;X Peng;M Plets;C Tangen;A Aparicio;B Chapin;D Quinn;D McConkey;T Dorff;I Thompson;T Triche;A Goldkorn
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 5036); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1802

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937

Authors
S Sadeghi;M Plets;P Lara;C Tangen;R Bangs;S Lerner;T Flaig;D Petrylak;I Thompson
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4608); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), tips, poster
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1937